Growth Hormone Therapy and Tumor Recurrence: Findings in Children With Brain Neoplasms and Hypopituitarism

Silva A. Arslanian, Dorothy J. Becker, Peter A. Lee, Allan L. Drash, Thomas P. Foley

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

We report the outcome of growth hormone (GH) therapy in 34 children (17 boys and 17 girls) with brain tumors in whom hypopituitarism developed. The types of tumors included the following: craniopharyngiomas (18); germinomas (four); astrocytomas (three); chromophobe adenomas (three); medulloblastomas (two); glioma (one); dermoid (one); retinoblastoma (one); and metastatic rhabdomyosarcoma from the pelvis (one). Ninety-four percent of the patients were GH deficient post–tumor therapy, which consisted of surgery with and without radiotherapy. Twenty-four of 34 patients received GH. Eight of 24 patients receiving GH had recurrence of tumor; 16 were tumor free eight to 72 months after initial therapy. Eleven patients had 12 recurrences. Patients with tumor recurrence had a considerably lower growth rate during the first year of GH therapy than those without recurrence (mean, 3.5 ± 1.3 cm/yr v 6.2 ± 2.5 cm/yr). Three of 11 patients with recurrence had not received GH therapy; however, one was receiving testosterone intramuscularly monthly at the time of a second recurrence. Thus, 24 of 34 patients with brain tumors and hypopituitarism received GH therapy. Eight (33%) of 24 had tumor recurrence, compared with three (30%) of ten who did not receive GH. The data suggest that GH therapy is probably not associated with increased rate of tumor recurrence.

Original languageEnglish (US)
Pages (from-to)347-350
Number of pages4
JournalAmerican Journal of Diseases of Children
Volume139
Issue number4
DOIs
StatePublished - Apr 1985

Fingerprint

Hypopituitarism
Brain Neoplasms
Growth Hormone
Recurrence
Neoplasms
Therapeutics
Chromophobe Adenoma
Germinoma
Craniopharyngioma
Dermoid Cyst
Medulloblastoma
Rhabdomyosarcoma
Retinoblastoma
Astrocytoma
Pelvis
Glioma
Testosterone
Radiotherapy

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Arslanian, Silva A. ; Becker, Dorothy J. ; Lee, Peter A. ; Drash, Allan L. ; Foley, Thomas P. / Growth Hormone Therapy and Tumor Recurrence : Findings in Children With Brain Neoplasms and Hypopituitarism. In: American Journal of Diseases of Children. 1985 ; Vol. 139, No. 4. pp. 347-350.
@article{796cd930976c44089a995be623789284,
title = "Growth Hormone Therapy and Tumor Recurrence: Findings in Children With Brain Neoplasms and Hypopituitarism",
abstract = "We report the outcome of growth hormone (GH) therapy in 34 children (17 boys and 17 girls) with brain tumors in whom hypopituitarism developed. The types of tumors included the following: craniopharyngiomas (18); germinomas (four); astrocytomas (three); chromophobe adenomas (three); medulloblastomas (two); glioma (one); dermoid (one); retinoblastoma (one); and metastatic rhabdomyosarcoma from the pelvis (one). Ninety-four percent of the patients were GH deficient post–tumor therapy, which consisted of surgery with and without radiotherapy. Twenty-four of 34 patients received GH. Eight of 24 patients receiving GH had recurrence of tumor; 16 were tumor free eight to 72 months after initial therapy. Eleven patients had 12 recurrences. Patients with tumor recurrence had a considerably lower growth rate during the first year of GH therapy than those without recurrence (mean, 3.5 ± 1.3 cm/yr v 6.2 ± 2.5 cm/yr). Three of 11 patients with recurrence had not received GH therapy; however, one was receiving testosterone intramuscularly monthly at the time of a second recurrence. Thus, 24 of 34 patients with brain tumors and hypopituitarism received GH therapy. Eight (33{\%}) of 24 had tumor recurrence, compared with three (30{\%}) of ten who did not receive GH. The data suggest that GH therapy is probably not associated with increased rate of tumor recurrence.",
author = "Arslanian, {Silva A.} and Becker, {Dorothy J.} and Lee, {Peter A.} and Drash, {Allan L.} and Foley, {Thomas P.}",
year = "1985",
month = "4",
doi = "10.1001/archpedi.1985.02140060029020",
language = "English (US)",
volume = "139",
pages = "347--350",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "4",

}

Growth Hormone Therapy and Tumor Recurrence : Findings in Children With Brain Neoplasms and Hypopituitarism. / Arslanian, Silva A.; Becker, Dorothy J.; Lee, Peter A.; Drash, Allan L.; Foley, Thomas P.

In: American Journal of Diseases of Children, Vol. 139, No. 4, 04.1985, p. 347-350.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Growth Hormone Therapy and Tumor Recurrence

T2 - Findings in Children With Brain Neoplasms and Hypopituitarism

AU - Arslanian, Silva A.

AU - Becker, Dorothy J.

AU - Lee, Peter A.

AU - Drash, Allan L.

AU - Foley, Thomas P.

PY - 1985/4

Y1 - 1985/4

N2 - We report the outcome of growth hormone (GH) therapy in 34 children (17 boys and 17 girls) with brain tumors in whom hypopituitarism developed. The types of tumors included the following: craniopharyngiomas (18); germinomas (four); astrocytomas (three); chromophobe adenomas (three); medulloblastomas (two); glioma (one); dermoid (one); retinoblastoma (one); and metastatic rhabdomyosarcoma from the pelvis (one). Ninety-four percent of the patients were GH deficient post–tumor therapy, which consisted of surgery with and without radiotherapy. Twenty-four of 34 patients received GH. Eight of 24 patients receiving GH had recurrence of tumor; 16 were tumor free eight to 72 months after initial therapy. Eleven patients had 12 recurrences. Patients with tumor recurrence had a considerably lower growth rate during the first year of GH therapy than those without recurrence (mean, 3.5 ± 1.3 cm/yr v 6.2 ± 2.5 cm/yr). Three of 11 patients with recurrence had not received GH therapy; however, one was receiving testosterone intramuscularly monthly at the time of a second recurrence. Thus, 24 of 34 patients with brain tumors and hypopituitarism received GH therapy. Eight (33%) of 24 had tumor recurrence, compared with three (30%) of ten who did not receive GH. The data suggest that GH therapy is probably not associated with increased rate of tumor recurrence.

AB - We report the outcome of growth hormone (GH) therapy in 34 children (17 boys and 17 girls) with brain tumors in whom hypopituitarism developed. The types of tumors included the following: craniopharyngiomas (18); germinomas (four); astrocytomas (three); chromophobe adenomas (three); medulloblastomas (two); glioma (one); dermoid (one); retinoblastoma (one); and metastatic rhabdomyosarcoma from the pelvis (one). Ninety-four percent of the patients were GH deficient post–tumor therapy, which consisted of surgery with and without radiotherapy. Twenty-four of 34 patients received GH. Eight of 24 patients receiving GH had recurrence of tumor; 16 were tumor free eight to 72 months after initial therapy. Eleven patients had 12 recurrences. Patients with tumor recurrence had a considerably lower growth rate during the first year of GH therapy than those without recurrence (mean, 3.5 ± 1.3 cm/yr v 6.2 ± 2.5 cm/yr). Three of 11 patients with recurrence had not received GH therapy; however, one was receiving testosterone intramuscularly monthly at the time of a second recurrence. Thus, 24 of 34 patients with brain tumors and hypopituitarism received GH therapy. Eight (33%) of 24 had tumor recurrence, compared with three (30%) of ten who did not receive GH. The data suggest that GH therapy is probably not associated with increased rate of tumor recurrence.

UR - http://www.scopus.com/inward/record.url?scp=0021963095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021963095&partnerID=8YFLogxK

U2 - 10.1001/archpedi.1985.02140060029020

DO - 10.1001/archpedi.1985.02140060029020

M3 - Article

C2 - 3976624

AN - SCOPUS:0021963095

VL - 139

SP - 347

EP - 350

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 4

ER -